
About Atara Biotherapeutics
Atara Biotherapeutics is a publicly listed company based in San Francisco (United States) founded in 2012. Targeted antibody and T-cell therapeutics are developed for multiple diseases. Atara Biotherapeutics has raised $52 million across 2 funding rounds from investors including ARE, Kleiner Perkins and Celgene. The company has 153 employees. Its website atarabio.com draws about 16 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Atara Biotherapeutics was founded in 2012 in San Francisco, United States, within the biotechnology sector. Antibody candidates targeting activin A for ovarian cancer and solid tumors, as well as myostatin for cancer cachexia and muscle loss from fractures, are advanced through the pipeline. Allogeneic T-cell therapies addressing Epstein-Barr virus, cytomegalovirus, and WT1 for various cancers are also pursued. Operations center on therapeutic development for infectious and oncologic conditions.
- Headquarters San Francisco, United States
- Employees 153
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website atarabio.com
- Social LinkedIn X
- Legal Name Atara Biotherapeutics, Inc.
- Annual Revenue$120.77 M (USD)-6.33as on Dec 31, 2025
- Net Profit$32.69 M (USD)as on Dec 31, 2025
- EBITDA$51.89 M (USD)as on Dec 31, 2025
- Total Equity Funding$52M (USD)
in 2 rounds
- Latest Funding Round$13.5M (USD), Series B
Jan 2014
- InvestorsARE
& 7 more
- Employee Count153
Funding Insights of Atara Biotherapeutics
Atara Biotherapeutics has successfully raised a total of $52M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $13.5 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52M
- Total Rounds 2
- Last Round Series B β $13.5M
- First Round $38.5M
(Dec 2013)
- Investors Count 8
All 2 funding rounds of Atara Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
8 investors in total: 8 institutional.
Investors in Atara Biotherapeutics
Atara Biotherapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Kleiner Perkins and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mid-stage venture capital investments and support for tech entrepreneurs. | dagventures.com | |||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Early stage investments focused VC firm | acks.com | |||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
| ecor1cap.com | ||||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Atara Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atara Biotherapeutics
76 people are tracked at Atara Biotherapeutics (44 in leadership, 5 in board & advisors, 27 in team); the tracked headcount is 153.
| Name | Role | Group |
|---|---|---|
Pascal Touchon | Chairman of the Board | Leadership |
Laurence Hanes Gamelin | VP Drug Safety & Pharmacovigilance | Leadership |
K. Amar Murugan | EVP & Chief Legal Officer | Leadership |
AJ Joshi | EVP & Chief Medical Officer | Leadership |
Chris Meyer | Operations Product Lead Director | Leadership |
Hadar Adams | Director, Analytical Development And Quality Control | Leadership |
Reddy Guda | Director Of Information Technology | Leadership |
Stephanie Triska | Director, Clinical Quality Assurance | Leadership |
Shailender Gunnala | Chief Information Officer | Leadership |
Cokey Nguyen | EVP & Chief Scientific & Technical Officer | Leadership |
Xianhui Chen | Associate Director | Leadership |
Joel Harris | Senior Director, Intellectual Property | Leadership |
Jill Henrich | EVP & Global Head Regulatory Affairs & Quality | Leadership |
Wenjin Cao | Associate Director, Quality Operations | Leadership |
Paula Kaplan-Lefko | Director Of Regulatory Affairs | Leadership |
Matt Verbrugge | Senior Director Program Management | Leadership |
Jake Buchholtz | Senior Director, Global Operations | Leadership |
Robyn Murphy | Director Clinical Program Management | Leadership |
Amy Gamber | Vice President Of Manufacturing | Leadership |
Guido Palermo | Sr. Director, External Manufacturing | Leadership |
56 more people are available in the full profile.
Complete people profiles for Atara Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Atara Biotherapeutics
Atara Biotherapeutics is a publicly listed company on the NASDAQ with ticker symbol ATRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Oct 2014
- Listed onNASDAQ: ATRA
- Listed entityAtara Biotherapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS0465132068
- Share price$9.30 (-0.8% on the day) · 2026-10-13
- Market capitalisation$93.4M
- Price to earnings6.9
- EPS (diluted, trailing year)$-1.40
- Volume (last session)32,286
Financials of Atara Biotherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $120.8M | $32.7M | $51.9M |
| 2024 | $128.9M | -$85.4M | -$75.6M |
| 2023 | $8.6M | -$276.1M | -$264.4M |
| 2022 | $63.6M | -$228.3M | -$260.0M |
| 2021 | $20.3M | -$340.1M | -$329.1M |
Detailed financial statements for Atara Biotherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Atara Biotherapeutics
4 dated milestones of Atara Biotherapeutics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Atara Biotherapeutics is founded.
- Funding First funding round of $38.5M.
- Funding Latest funding round, Series B, of $13.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of Atara Biotherapeutics
Atara Biotherapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Atara Biotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Atara Biotherapeutics
The website of Atara Biotherapeutics (atarabio.com) receives about 16.1K visits a month and ranks #3,186,600 among all websites worldwide, #4,194 in Biotechnology and Pharmaceuticals.
- Monthly visits16.1K
▲ 144.1% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,186,600
among all websites
- Category rank#4,194
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.6
- Average visit9 sec
- DevicesDesktop 42% Β· Mobile 58%
Websites whose visitors overlap most with Atara Biotherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vaxart.com | 100% | 4.8K | #4,483,544 | View details | |
ampliphibio.com | ampliphibio.com | 98% | β | ||
| dynavax.com | 97% | 11K | #2,032,192 | View details | |
| bellicum.com | 96% | 1.8K | #8,642,421 | View details | |
ddn-news.com | ddn-news.com | 96% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 15 similar websites and full traffic analytics for Atara Biotherapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Atara Biotherapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Atara Biotherapeutics
Complete news archive for Atara Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atara Biotherapeutics
Atara Biotherapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Atara Biotherapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Atara Biotherapeutics is a funded company, having raised a total of $52M across 2 funding rounds to date. The company's 1st funding round was a Series B of $38.5M, raised on Dec 2013.
Atara Biotherapeutics has 153 employees.
Annual revenue of Atara Biotherapeutics is $120.77M as on Dec 31, 2025.
Atara Biotherapeutics was founded in 2012 in San Francisco, United States, within the biotechnology sector. Antibody candidates targeting activin A for ovarian cancer and solid tumors, as well as myostatin for cancer cachexia and muscle loss from fractures, are advanced through the pipeline. Allogeneic T-cell therapies addressing Epstein-Barr virus, cytomegalovirus, and WT1 for various cancers are also pursued. Operations center on therapeutic development for infectious and oncologic conditions.
Yes, Atara Biotherapeutics is publicly traded on NASDAQ under the ticker symbol ATRA.
Atara Biotherapeutics has 8 investors. Key investors include ARE, Kleiner Perkins, Celgene, EcoR1, and DAG Ventures.
